Vir Biotechnology Inc. (NASDAQ: VIR) is 138.42% higher on its value in year-to-date trading and has touched a low of $17.03 and a high of $141.01 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VIR stock was last observed hovering at around $68.77 in the last trading session, with the day’s loss setting it -4.92% off its average median price target of $61.50 for the next 12 months. It is also 48.92% off the consensus price target high of $125.00 offered by 7 analysts, but current levels are -112.83% lower than the price target low of $30.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $63.85, the stock is -7.61% and 36.23% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.2 million and changing -7.15% at the moment leaves the stock 58.74% off its SMA200. VIR registered 236.76% gain for a year compared to 6-month loss of 20.79%. The firm has a 50-day simple moving average (SMA 50) of $54.59 and a 200-day simple moving average (SMA200) of $40.03.
The stock witnessed a 57.54% gain in the last 1 month and extending the period to 3 months gives it a 122.32%, and is -5.24% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.68% over the week and 22.84% over the month.
Vir Biotechnology Inc. (VIR) has around 297 employees, a market worth around $7.41B and $75.60M in sales. Distance from 52-week low is 274.93% and -54.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.90%).
Vir Biotechnology Inc. (VIR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Vir Biotechnology Inc. (VIR) is a “Overweight”. 7 analysts offering their recommendations for the stock have an average rating of 2.10, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Vir Biotechnology Inc. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.7 with sales reaching $4.81M over the same period.The EPS is expected to shrink by -443.30% this year, but quarterly earnings will post 876.30% year-over-year. Quarterly sales are estimated to grow 390.80% in year-over-year returns.
Vir Biotechnology Inc. (VIR) Top Institutional Holders
154 institutions hold shares in Vir Biotechnology Inc. (VIR), with 18.04M shares held by insiders accounting for 14.16% while institutional investors hold 92.73% of the company’s shares. The shares outstanding are 125.81M, and float is at 109.35M with Short Float at 9.01%. Institutions hold 79.61% of the Float.
The top institutional shareholder in the company is SB Investment Advisers (UK) LTD with over 22.62 million shares valued at $605.67 million. The investor’s holdings represent 17.75% of the VIR Shares outstanding. As of Dec 30, 2020, the second largest holder is Capital International Investors with 11.3 million shares valued at $302.64 million to account for 8.87% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 5.87 million shares representing 4.61% and valued at over $157.2 million, while Temasek Holdings (Private) Limited holds 4.32% of the shares totaling 5.5 million with a market value of $147.29 million.
Vir Biotechnology Inc. (VIR) Insider Activity
A total of 80 insider transactions have happened at Vir Biotechnology Inc. (VIR) in the last six months, with sales accounting for 33 and purchases happening 47 times. The most recent transaction is an insider sale by Virgin Herbert, the company’s EVP, Research & CSO. SEC filings show that Virgin Herbert sold 7,900 shares of the company’s common stock on Feb 09 at a price of $71.16 per share for a total of $0.56 million. Following the sale, the insider now owns 33200.0 shares.
Vir Biotechnology Inc. disclosed in a document filed with the SEC on Feb 01 that Parrish Jay (Chief Business Officer) sold a total of 6,944 shares of the company’s common stock. The trade occurred on Feb 01 and was made at $69.91 per share for $0.49 million. Following the transaction, the insider now directly holds 0.22 million shares of the VIR stock.
Still, SEC filings show that on Jan 26, Virgin Herbert (EVP, Research & CSO) disposed off 31,300 shares at an average price of $48.17 for $1.51 million. The insider now directly holds 33,200 shares of Vir Biotechnology Inc. (VIR).